Hepatitis C and beta-thalassemia major in children: experience with glecaprevir/pibrentasvir

Abstract

Hepatitis C virus (HCV) is estimated to affect 3.26 million children worldwide, with the highest number of cases registered in Pakistan and China. Vertical transmission is the principal route in industrialized countries. However, iatrogenic transmission is relevant in low-income settings. We present the case of a 12-year-old Pakistani child who suffered from beta-thalassemia major and hepatitis C, successfully treated with glecaprevir/pibrentasvir.